pISSN 2234-3806eISSN 2234-3814
| Characteristics | N (%) |
|---|---|
| Age (yrs) |
72 (63, 78) |
| Female sex | 975 (39.7) |
| Ontogeny | |
| Primary | 2185 (89.0) |
| Secondary/therapy-related | 207 (8.4) |
| NA | 62 (2.5) |
| WHO 2017 classification | |
| MDS-del(5q) | 139 (5.7) |
| MDS-SLD | 191 (7.8) |
| MDS-MLD | 639 (26.0) |
| MDS-SLD/MLD |
91 (3.7) |
| MDS-RS-SLD | 246 (10.0) |
| MDS-RS-MLD | 212 (8.6) |
| MDS-RS-SLD/MLD |
3 (0.1) |
| MDS-EB-1 | 458 (18.7) |
| MDS-EB-2 | 429 (17.5) |
| MDS-U | 46 (1.9) |
| IPSS-R | |
| Very low | 383 (15.6) |
| Low | 917 (37.4) |
| Intermediate | 482 (19.6) |
| High | 312 (12.7) |
| Very high | 253 (10.3) |
| NA | 107 (4.4) |
| IPSS-M | |
| Very low | 302 (12.3) |
| Low | 746 (30.4) |
| Moderately low | 258 (10.5) |
| Moderately high | 244 (9.9) |
| High | 325 (13.2) |
| Very high | 430 (17.5) |
| NA | 149 (6.1) |
| Disease-modifying treatment | |
| None | 1662 (67.7) |
| Lenalidomide alone | 140 (5.7) |
| HMAs |
377 (15.4) |
| Intensive chemotherapy |
28 (1.1) |
| Transplantation|| | 247 (10.1) |
*Ages are presented as median with interquartile range; data for one patient was missing.
†“MDS-SLD/MLD” and “MDS-RS-SLD/MLD” indicate that the number of dysplastic lineages was not specified, based on the pre-existing diagnosis assigned by Bernard, et al. [9].
‡HMAs (plus lenalidomide).
§Intensive chemotherapy (plus HMAs).
||Hematopoietic stem cell transplantation (plus lenalidomide, HMA, or intensive chemotherapy).
Abbreviations: NA, not assessed; -del(5q), with isolated del(5q); -SLD, with single lineage dysplasia; -MLD, with multilineage dysplasia; -RS, with ring sideroblasts; -EB, with excess blasts; MDS-U, MDS, unclassifiable; IPSS-R, Revised International Prognostic Scoring System; IPSS-M, Molecular International Prognostic Scoring System; HMAs, hypomethylating agents.
© Ann Lab Med